Ozempic Gastroparesis Settlement: New York Ozempic Gastroparesis Injury Lawyer

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Drug Safety Concerns

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy of accessible, broad-spectrum health education has empowered individuals to make informed decisions about their well-being, from managing chronic diseases to navigating pharmaceutical therapies. Within this framework, the public has come to rely on clear, neutral guidance regarding the benefits and potential risks associated with widely prescribed medications. As the landscape of therapeutic interventions evolves, so too does the need to address emerging concerns that arise from real-world clinical use. One such area of growing attention involves the long-term effects of glucagon-like peptide-1 receptor agonists, a class of drugs originally developed for metabolic regulation. Recent observational data have prompted a shift in focus from general metabolic health to specific adverse outcomes that may occur in certain patient populations. This pivot naturally leads to a more targeted inquiry: the potential association between sustained exposure to these agents and the development of gastrointestinal motility disorders. In particular, the risk of gastroparesis—a condition characterized by delayed gastric emptying—has become a subject of legal and medical scrutiny. For individuals who have experienced such complications, the question of accountability and compensation has moved from the realm of general health discussion into the specialized domain of pharmaceutical injury litigation.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In pooled placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 32.7% with Ozempic 0.5 mg, 36.4% with Ozempic 1 mg, and 15.3% with placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 34.0% of patients on 2 mg versus 30.8% on 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Gastroparesis: Symptoms, Diagnosis, and Link to Ozempic

Gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction, presents with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy or breath tests. The mechanistic link between GLP-1 receptor agonists like Ozempic and gastroparesis is grounded in the pharmacology of these agents: GLP-1 slows gastric emptying as part of its incretin effect, which can become pathologically prolonged in susceptible individuals. While the Ozempic label does not explicitly list gastroparesis as an adverse reaction, it does report related gastrointestinal conditions. For instance, in clinical trials, dyspepsia occurred in 3.5% of patients on Ozempic 0.5 mg and 2.7% on 1 mg, compared to 1.9% on placebo; gastroesophageal reflux disease occurred in 1.9% on 0.5 mg and 1.5% on 1 mg, versus 0% on placebo; and gastritis occurred in 0.8% on both doses, versus 0.8% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, and the drug's known effect on gastric motility raises concern for a causal pathway.

Legal Implications and Settlement Considerations for New York Patients

The adequacy of warnings regarding Ozempic and gastroparesis is a key risk consideration. The current prescribing information for Ozempic includes a section on hypersensitivity reactions, noting that serious hypersensitivity events such as anaphylaxis and angioedema have been reported, and caution is advised for patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a potential adverse effect, despite the mechanistic plausibility and the reported gastrointestinal adverse reactions that align with gastroparesis symptoms. This gap in explicit warning may be relevant for patients who develop severe or persistent gastrointestinal symptoms after starting Ozempic, particularly if those symptoms lead to significant morbidity, such as malnutrition, dehydration, or hospitalization. For affected patients in New York, settlement-related considerations involve documenting the timeline between Ozempic exposure and the onset of gastroparesis symptoms. The clinical trials indicate that gastrointestinal adverse reactions often occur during dose escalation, but the label does not specify a typical latency for gastroparesis specifically. Patients who experience symptoms such as persistent nausea, vomiting, or abdominal pain after initiating Ozempic should seek medical evaluation to confirm a diagnosis of gastroparesis through objective testing. The harm must be temporally linked to the drug exposure, and alternative causes (e.g., diabetic gastroparesis, prior surgery, or other medications) should be excluded. Legal claims may hinge on whether the manufacturer provided adequate warnings about the risk of gastroparesis, given the known effects of GLP-1 agonists on gastric emptying. In summary, the evidence from clinical trials shows a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, including symptoms that overlap with gastroparesis. The mechanistic pathway is biologically plausible, but the label does not explicitly warn about gastroparesis. Patients in New York who have developed gastroparesis after using Ozempic should consider consulting a medical professional for diagnosis and a legal professional to evaluate potential claims related to inadequate warnings and harm. References: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In susceptible individuals, this effect can become pathologically prolonged, leading to gastroparesis. Clinical trials show higher rates of gastrointestinal adverse reactions with Ozempic compared to placebo, including symptoms that overlap with gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the current prescribing information for Ozempic does not explicitly list gastroparesis as an adverse reaction. It does report related gastrointestinal conditions such as dyspepsia, gastroesophageal reflux disease, and gastritis, but does not specifically warn about gastroparesis despite the mechanistic plausibility (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should New York patients do if they developed gastroparesis after taking Ozempic?

Patients should seek medical evaluation to confirm a diagnosis of gastroparesis through objective testing such as gastric emptying scintigraphy. They should document the timeline between Ozempic exposure and symptom onset, and consult a legal professional to evaluate potential claims related to inadequate warnings and harm.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.